<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938144</url>
  </required_header>
  <id_info>
    <org_study_id>B3971002</org_study_id>
    <nct_id>NCT01938144</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America</brief_title>
  <official_title>Four-day Clinical Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Symptomatic Treatment of the Common Cold and Flu</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics Research</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, double-blind, parallel group, comparative,
      non-inferiority study designed to evaluate the efficacy of Ibuprofen (IBU) 200 mg/
      Phenylephrine (PE) 10 mg and IBU 200 mg/ PE 10 mg/ Chlorpheniramine (CHLOR) 4 mg on the
      relief of symptoms of the common cold and flu. The reference product that the active
      treatments will be compared to is paracetamol (PARA) 500 mg.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in the sum of 4 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing and head congestion), averaged over 3 days obtained from the Wisconsin Upper Respiratory Symptom Survey - 21</measure>
    <time_frame>3 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the sum of 4 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing and head congestion), averaged over 3 days obtained from the Wisconsin Upper Respiratory Symptom Survey - 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the sum of all 10 symptoms, averaged over 3 days.</measure>
    <time_frame>3 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AM assessment of symptom relief reflective over the past 12 hours.</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PM assessment of symptom relief reflective over the past 12 hours.</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The severity of cold/flu symptoms will be determined by the subject's response to the Wisconsin Upper Respiratory Symptom Survey, which includes questions related to the signs and symptoms of cold and flu, as well as Quality of Life Measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom relief since taking the first dose.</measure>
    <time_frame>60 min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU 200 mg/ PE 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBU 200 mg/ PE 10 mg/CHLOR 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advil Congestion Relief</intervention_name>
    <description>Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 12 doses.</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advil Allergy and Congestion Relief</intervention_name>
    <description>Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 12 doses.</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Acetaminophen 500 mg, 4x/day, up to 12 doses.</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female subjects who are 18 years old or older at the time of screening.

        Subjects who are willing and able to comply with scheduled visits, treatment plan,
        laboratory tests, and other study procedures.

        Subjects must present with a score of 5 of higher for at least 1 of the following 4
        symptoms: runny nose, plugged nose, sneezing, or head congestion on the WURSS-21
        assessment, within 36 hours of onset of symptoms.

        Exclusion Criteria:

        Anyone with a history of chronic allergic rhinitis or asthma at the time of the screening
        visit, or with history of chronic recurrent airway disease, infections, or frequent
        complications of colds (otitis media, sinusitis, or bronchitis)

        Subjects taking any other type of cold remedies within the last 7 days prior to the
        screening (Appendix 2), as well as those subjects who are taking antibiotics of any kind.

        Subjects with a hypersensitivity to IBU, PE, or CHLOR or APAP.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3971002&amp;StudyName=Evaluation%20of%20the%20Efficacy%20and%20Safety%20of%20Two%20Ibuprofen%20Combination%20Products%20for%20the%20Treatment%20of%20the%20Common%20Cold%20and%20Flu%20in%20Latin%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Common cold</keyword>
  <keyword>efficacy</keyword>
  <keyword>symptoms</keyword>
  <keyword>Wisconsin Upper Respiratory Symptom Survey - 21</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>pseudoephedrine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
